Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.035
Sell
RSI(14)
30.648
Neutral
STOCH(KDJ)(9,3,3)
33.214
Sell
ATR(14)
0.118
High Vlolatility
CCI(14)
-226.957
Oversold
Williams %R
76.923
Sell
TRIX(12,20)
-0.533
Sell
StochRSI(14)
0.000
Sell
Search
Microbot Medical Inc
MBOTAdd to Watchlist
1.850USD
0.0000.00%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
124.25MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Microbot Medical Inc
Currency: USD Updated: 2026-05-15Key Insights
Microbot Medical Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 138 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Microbot Medical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Microbot Medical Inc Highlights
StrengthsRisks
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -7.17, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 15.51M shares, increasing 25.62% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 29.42K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.500
Target Price
+305.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Microbot Medical Inc is 5.51, ranking 344 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.75
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Microbot Medical Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Microbot Medical Inc is 7.00, ranking 179 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.17, which is -91.41% below the recent high of -0.62 and -25.85% above the recent low of -9.02.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 138/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Microbot Medical Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.75, with a high of 12.00 and a low of 5.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.500
Target Price
+305.41%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Microbot Medical Inc
MBOT
3
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Microbot Medical Inc is 6.76, ranking 159 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.20 and the support level at 1.61, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.050
Sell
MA10
2.091
Sell
MA20
2.123
Sell
MA50
2.347
Sell
MA100
2.223
Sell
MA200
2.520
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Microbot Medical Inc is 3.58, ranking 128 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.08
VaR
+7.09%
240-Day Maximum Drawdown
+64.00%
240-Day Volatility
+85.63%
Return
Best Daily Return
60 days
+23.90%
120 days
+23.90%
5 years
+159.29%
Worst Daily Return
60 days
-14.75%
120 days
-14.75%
5 years
-33.91%
Sharpe Ratio
60 days
-0.27
120 days
+0.29
5 years
+0.23
Risk Assessment
Maximum Drawdown
240 days
+64.00%
3 years
+71.89%
5 years
+90.77%
Return-to-Drawdown Ratio
240 days
-0.48
3 years
-0.17
5 years
-0.16
Skewness
240 days
+0.95
3 years
+4.40
5 years
+9.48
Volatility
Realised Volatility
240 days
+85.63%
5 years
+106.14%
Standardised True Range
240 days
+10.33%
5 years
+11.43%
Downside Risk-Adjusted Return
120 days
+55.40%
240 days
+55.40%
Maximum Daily Upside Volatility
60 days
+71.49%
Maximum Daily Downside Volatility
60 days
+61.57%
Liquidity
Average Turnover Rate
60 days
+4.80%
120 days
+5.40%
5 years
--
Turnover Deviation
20 days
-38.01%
60 days
-34.62%
120 days
-26.45%
Peer Comparison
Biotechnology & Medical Research
Microbot Medical Inc
MBOT
6.04 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
